Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Revenue of Arbutus Biopharma Corporation (ABUS)
Revenue in 2023 (TTM): $18.14 M
According to Arbutus Biopharma Corporation's latest financial reports the company's current revenue (TTM) is $18.14 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Arbutus Biopharma Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $18.14 M | $-55,559,000 | $-70,986,000 | $-72,849,000 | $-72,849,000 |
| 2022 | $39.02 M | $37.59 M | $-61,859,000 | $-65,012,000 | $-69,456,000 |
| 2021 | $10.99 M | $9.24 M | $-71,637,000 | $-76,247,000 | $-77,351,000 |
| 2020 | $6.91 M | $-40,567,000 | $-57,806,000 | $-63,745,000 | $-65,211,000 |
| 2019 | $6.01 M | $-51,590,000 | $-147,321,000 | $-166,379,000 | $-153,723,000 |
| 2018 | $5.9 M | $-52,000,000 | $-58,953,000 | $-61,400,000 | $-57,100,000 |
| 2017 | $10.7 M | $-52,000,000 | $-106,445,000 | $-108,700,000 | $-84,400,000 |
| 2016 | $1.5 M | $-59,800,000 | $-488,074,000 | $-489,100,000 | $-384,100,000 |
| 2015 | $24.87 M | $-26,632,000 | $-76,717,000 | $-77,306,000 | $-61,121,000 |
| 2014 | $15 M | $-23,700,000 | $-32,442,999 | $-38,700,000 | $-38,800,000 |
| 2013 | $15.46 M | $-5,994,108 | $-11,539,000 | $-14,064,226 | $-14,064,226 |
| 2012 | $14.18 M | $-3,944,634 | $34.18 M | $29.95 M | $29.95 M |
| 2011 | $16.3 M | $-3,185,138 | $-9,057,554 | $-9,854,827 | $-9,732,543 |
| 2010 | $21.35 M | $-779,120 | $-11,045,278 | $-12,520,434 | $-12,413,494 |
| 2009 | $13.78 M | $-3,185,907 | $-6,735,567 | $-9,482,001 | $-9,325,668 |
| 2008 | $9.64 M | $-3,608,567 | $-7,227,325 | $-11,718,097 | $-11,718,097 |
| 2007 | $15.92 M | $15.92 M | $3.05 M | $-2,582,571 | $-2,582,571 |
| 2006 | $13.6 M | $7.42 M | $20.97 M | $18.08 M | $18.08 M |
| 2005 | $13.29 M | $13.29 M | $1.31 M | $-7,671,034 | $-8,059,359 |
| 2004 | $12.17 M | $12.17 M | $-17,903,704 | $-29,802,400 | $-28,049,879 |
| 2003 | $2.73 M | $2.73 M | $-27,758,566 | $ | $-34,076,487 |
| 2002 | $5.07 M | $5.07 M | $-22,061,452 | $ | $-26,794,342 |
| 2001 | $3.46 M | $3.46 M | $-12,573,827 | $-15,956,262 | $-14,015,235 |
| 2000 | $1.77 M | $1.77 M | $-9,413,019 | $ | $-9,202,926 |
| 1999 | $1.14 M | $1.14 M | $-6,868,493 | $ | $-8,173,034 |
| 1998 | $1.23 M | $1.23 M | $-7,764,086 | $ | $-8,753,865 |